Comparison of oral contraceptives including Contrasmine, Etisterone and Desoceptive with Ovustop-L (LD) on clinical, biochemical and metabolic findings, and quality of life in women with polycystic ovary syndrome.
Phase 3
- Conditions
- Polycystic ovary syndrome.Sclerocystic ovary syndrome Stein-Leventhal syndrome
- Registration Number
- IRCT201702071281N2
- Lead Sponsor
- Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
inclusion criteria: Existent of diagnostic criteria for polycystic ovary syndrome based on Androgen Excess and PCOS Society (AES), Lack of pregnancy diagnosis and tendency to it for a year or more, lack of using hormonal, anti-androgens or sensitizers drugs at least 3 months before the study, Failure to detect other causes of hyperandrogenism, Not having chronic medical conditions, high and severe blood pressure, recent surgery or known cancer, 6- Not smoking and non-obesity.
Exclusion criteria: Not adherence to prescribed medications for more than two months, detection of chronic medical disorders, Appearing the serious effects such as thrombosis contraceptive.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Free Androgen Index (FAI). Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: According to the formula of total testosterone (nmol/ L)) x 100 /sex hormone-binding globulin).
- Secondary Outcome Measures
Name Time Method